Abstract RF4-03: Evaluation of a whole-exome sequencing tumor-informed circulating tumor DNA MRD assay in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without atezolizumab: A prospective sub study of the NSABP-B59/GBG-96-GeparDouze Trial
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: M. Balic, G. Tang, G. Young, P. Rastogi, J. Acosta, A. Schneeweiss, C. Hilton, T. Freeman, C. Denkert, M. Reinisch, M. R. Palomares, A. A. Bradley, S. Murali, J. Boileau, D. Boudreau, P. J. Polewski, S. Hassan, J. Mouta, W. C. Darbonne, F. L. Baehner, E. P. Mamounas, N. Wolmark, S. Loibl, C. E. Geyer
Institutions: University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, NSABP Foundation, NRG Oncology, UPMC Health System, Allegheny Health Network, German Cancer Research Center, University Hospital Heidelberg, National Center for Tumor Diseases, Philipps University of Marburg, Heidelberg University, University Medical Centre Mannheim, Jewish General Hospital, McGill University, Hôpital du Saint-Sacrement, Aurora Health Care, Centre Hospitalier de l’Université de Montréal, Université de Montréal, Roche (Switzerland), Genentech, AdventHealth Orlando, AdventHealth, Goethe University Frankfurt, German Breast Group
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7129318388